Clinical Trial Update: A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 pilot study evaluating continuous subcutaneous pramlintide infusion in Type 1 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Symlin (pramlintide)

Snippet

Sponsor: University Diabetes & Endocrine Consultants | Conditions: IDDM | Phase 4 | Status: COMPLETED